Stephen Shumack

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 12

Top Topics

Artificial Intelligence

Atopic Dermatitis

Placebo Controlled

Top Venues

The Australasian journal of dermatology

Dermatology and therapy

This page only lists publications with an associated author ORCID identifier.

Publications

Åsa Ingvar, Ayooluwatomiwa Oloruntoba, Maithili Sashindranath, Robert Miller, Hans Peter Soyer, Pascale Guitera, Tony Caccetta, Stephen Shumack, Lisa M Abbott, Chris Arnold, Craig Lawn, Alison Button-Sloan, Monika Janda, Victoria Mar
Minimum labelling requirements for dermatology artificial intelligence-based Software as Medical Device (SaMD): A consensus statement. The Australasian journal of dermatology (2024)
Åsa Ingvar, Ayooluwatomiwa Oloruntoba, Maithili Sashindranath, Robert Miller, Hans Peter Soyer, Pascale Guitera, Tony Caccetta, Stephen Shumack, Lisa M Abbott, Chris Arnold, Craig Lawn, Alison Button-Sloan, Monika Janda, Victoria Mar
Minimum labelling requirements for dermatology artificial intelligence-based Software as Medical Device (SaMD): A consensus statement. The Australasian journal of dermatology 65 (3) (2024)
Marius Rademaker, Paul Jarrett, Dedee Frances Murrell, Rodney Daniel Sinclair, Lauren Pasfield, David Poppelwell, Stephen Shumack
Cross-sectional burden-of-illness study in atopic dermatitis (MEASURE-AD) in Australia and New Zealand reveals impacts on well-being. The Australasian journal of dermatology (2024)
Peter Foley, Kurt Gebauer, John R Sullivan, Erin K McMeniman, Stephen Shumack, Jonathan Ng, Amelia C James, Morton Rawlin, Shireen Sidhu, Dev Tillakaratne, Murray Turner, Barbara Radulski, Peter Nash, Christopher Baker
Australian consensus: Treatment goals for moderate to severe psoriasis in the era of targeted therapies - Adult patients. The Australasian journal of dermatology (2023)
Stephen K Tyring, Phoebe Rich, Yayoi Tada, Stefan Beeck, Izabella Messina, Jie Liu, Xiaohong Huang, Stephen Shumack
Risankizumab in Patients with Moderate-to-Severe Atopic Dermatitis: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study. Dermatology and therapy (2023)
Stephen K Tyring, Phoebe Rich, Yayoi Tada, Stefan Beeck, Izabella Messina, Jie Liu, Xiaohong Huang, Stephen Shumack
Risankizumab in Patients with Moderate-to-Severe Atopic Dermatitis: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study. Dermatology and therapy 13 (2) (2023)
Robert Sinclair, Xin Lin Wong, Stephen Shumack, Christopher Baker, Beth MacMahon
The role of micrometastasis in high-risk skin cancers. The Australasian journal of dermatology 65 (2) (2023)
Robert Sinclair, Xin Lin Wong, Stephen Shumack, Christopher Baker, Beth MacMahon
The role of micrometastasis in high-risk skin cancers. The Australasian journal of dermatology (2023)
Stephen K Tyring, Phoebe Rich, Yayoi Tada, Stefan Beeck, Izabella Messina, Jie Liu, Xiaohong Huang, Stephen Shumack
Risankizumab in Patients with Moderate-to-Severe Atopic Dermatitis: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study. Dermatology and therapy (2023)
Robert Sinclair, Xin Lin Wong, Stephen Shumack, Christopher Baker, Beth MacMahon
The role of micrometastasis in high-risk skin cancers. The Australasian journal of dermatology 65 (2) (2023)
Peter Foley, Yves A Kerdraon, John P Hogden, Stephen Shumack, Lynda Spelman, Deshan Frank Sebaratnam, Charles S Su, Constance H Katelaris
Dupilumab-associated ocular surface disease: An interdisciplinary decision framework for prescribers in the Australian setting. The Australasian journal of dermatology 63 (4) (2022)
Dale Jobson, Benjamin Roffey, Christopher Arnold, Anthony Azzi, Alison Button-Sloan, Tamara Dawson, Pablo Fernandez-Penas, Paul Fishburn, David E Gyorki, Emma L Hiscutt, Valerie Jakrot, Alister Lilleyman, Alistair Lochhead, Georgina V Long, Sonia Mailer, Graham J Mann, Christopher J McCormack, James Muir, George F Pratt, Richard A Scolyer, Mark Shackleton, Stephen Shumack, Hans Peter Soyer, Chin-Guan Tan, Angela Webb, Zalcberg John, Rachael Lisa Morton, Victoria J Mar
Development of melanoma clinical quality indicators for the Australian melanoma clinical outcomes registry (MelCOR): A modified Delphi study. The Australasian journal of dermatology 63 (3) (2022)